Plain-English translation of NCT07371208 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Breast Cancer research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether two medications called Sacituzumab Tirumotecan and KL-A167, given together before surgery, can help treat triple-negative breast cancer more effectively. Triple-negative breast cancer is a subtype that doesn't respond to some common hormone-based treatments, so researchers are exploring this new combination approach. The study will enroll 40 patients to see how well this medication works and what side effects patients experience.
Triple-negative breast cancer is harder to treat than other types of breast cancer because it doesn't respond to hormone therapies. This trial exists to test whether this new medication combination can shrink tumors before surgery and improve outcomes for patients with this challenging form of cancer.
You likely qualify if…
You likely don't qualify if…
You would receive the medication combination as an infusion or injection during a neoadjuvant phase (before your surgery), with visits to the hospital or clinic for treatment sessions and monitoring. The study team will check your overall health, do blood tests, and assess how well the treatment is working. After you complete the medication phase, you would proceed to surgery as planned, and the researchers will follow up to see how effective the treatment was.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
China